LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Consensus Recommendation of “Moderate Buy” by Analysts

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has received a consensus recommendation of “Moderate Buy” from the nine research firms that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $94.57.

A number of research firms have recently weighed in on LMAT. Cantor Fitzgerald started coverage on shares of LeMaitre Vascular in a report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price target on the stock. Barrington Research increased their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research report on Friday, November 1st. Oppenheimer reaffirmed an “outperform” rating and issued a $93.00 price target (up from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. Finally, StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th.

LeMaitre Vascular Stock Down 0.1 %

Shares of NASDAQ:LMAT opened at $92.12 on Monday. The firm has a 50 day moving average of $97.75 and a 200 day moving average of $90.07. The company has a market capitalization of $2.07 billion, a price-to-earnings ratio of 50.34, a price-to-earnings-growth ratio of 2.47 and a beta of 0.93. LeMaitre Vascular has a 52 week low of $52.88 and a 52 week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, topping the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The firm had revenue of $54.82 million during the quarter, compared to analyst estimates of $53.50 million. During the same period in the previous year, the company posted $0.33 EPS. The business’s revenue for the quarter was up 15.6% compared to the same quarter last year. On average, sell-side analysts expect that LeMaitre Vascular will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, December 5th. Investors of record on Thursday, November 21st were given a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 0.69%. The ex-dividend date was Thursday, November 21st. LeMaitre Vascular’s payout ratio is 34.97%.

Insider Buying and Selling

In related news, Director Bridget A. Ross sold 3,750 shares of LeMaitre Vascular stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $101.47, for a total transaction of $380,512.50. Following the completion of the sale, the director now owns 2,278 shares of the company’s stock, valued at $231,148.66. The trade was a 62.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 10.79% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On LeMaitre Vascular

A number of institutional investors have recently bought and sold shares of LMAT. Driehaus Capital Management LLC raised its stake in shares of LeMaitre Vascular by 52.2% during the 2nd quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier’s stock valued at $21,740,000 after buying an additional 90,573 shares during the last quarter. F M Investments LLC acquired a new stake in LeMaitre Vascular during the second quarter worth about $7,443,000. DF Dent & Co. Inc. raised its position in LeMaitre Vascular by 26.2% during the third quarter. DF Dent & Co. Inc. now owns 258,767 shares of the medical instruments supplier’s stock valued at $24,037,000 after acquiring an additional 53,797 shares in the last quarter. Nicholas Investment Partners LP acquired a new position in LeMaitre Vascular in the second quarter valued at approximately $3,900,000. Finally, Conestoga Capital Advisors LLC boosted its position in LeMaitre Vascular by 1.9% in the 3rd quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier’s stock worth $183,769,000 after purchasing an additional 36,850 shares in the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.